There are currently 292 active clinical trials seeking participants for Prostate Cancer research studies. The states with the highest number of trials for Prostate Cancer participants are California, New York, Texas and Ohio.
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737
Recruiting
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy,
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Cancer and Hematology Centers of Western Michigan ( Site 0015), Grand Rapids, Michigan +23 locations
Conditions: Prostate Cancer, Prostatic Neoplasms
Register for Updates
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
NCT06450106
Recruiting
A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Arizona Urology Specialists, Tucson, Arizona +3 locations
Conditions: Prostate Cancer
Register for Updates
Designing Visual Tools to Enhance Cancer Surgeon Decision-making
NCT06965192
Recruiting
This prospective study will compare pre-post pilot test of surgeon-facing, visual decision support among urologists seeing patients with newly diagnosed localized prostate and kidney cancer. Up to 20 urologists (10 academic and 10 community) will be enrolled. The goal will be to capture up to 10 pre- and 10 post-intervention patient encounters for each urologist with an accrual target of 200 unique patient visits (100 pre and 100 post-intervention) over a half-year period. Patient encounters pre... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina +1 locations
Conditions: Prostate Cancer, Kidney Cancer
Register for Updates
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
NCT06555796
Recruiting
The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: University of Minnesota Medical Center Fairview, Minneapolis, Minnesota +7 locations
Conditions: Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
Register for Updates
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
NCT04751435
Recruiting
Genetic testing is a type of test that detects changes to the genes-the DNA instructions that are passed on from the mother and father. The results of a genetic test can confirm whether the participant has a genetic disorder, which is a disease caused in whole or in part by changes to the genes. Genetic testing can also help determine a person's chance of getting or passing on a genetic disorder. Genetic tests use a sample of blood, hair, skin, or other tissue, and they can look at one gene or m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Kings County Hopsital Center, Brooklyn, New York +3 locations
Conditions: Educational Materials for Genetic Testing, Breast Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Colorectal Cancer
Register for Updates
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
NCT06395753
Recruiting
The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Bakersfield Institute of Advanced Urology, Bakersfield, California +26 locations
Conditions: Prostate Cancer
Register for Updates
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
NCT05804318
Recruiting
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Duarte Cancer Center, Duarte, California +4 locations
Conditions: Prostate Cancer
Register for Updates
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479
Recruiting
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: AdventHealth Orlando, Orlando, Florida +24 locations
Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Register for Updates
A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer
NCT04997018
Recruiting
One of the usual approaches to treating intermediate-risk prostate cancer is a type of radiation therapy called SBRT (stereotactic body radiation therapy). SBRT delivers higher than standard doses of radiation over a lower number of treatment sessions. However, there is a 20% chance that intermediate-risk prostate cancer will come back after this treatment. The purpose of this study is to find out whether giving an even higher dose (a "boost" dose) of radiation directly to the main tumor and the... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Victoria Brennan, Basking Ridge, New Jersey +6 locations
Conditions: Prostate Cancer
Register for Updates
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194
Recruiting
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Sarah Cannon Research Institute, Denver, Colorado +5 locations
Conditions: Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer
Register for Updates
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
NCT04486755
Recruiting
A phase I trial to determine the safety of delivering three sequentially shorter RT schedules (20, 16, and 12 fractions) of HypoFx pelvic nodal RT in combination with a HypoFx, simultaneous integrated boost (SIB) to the prostate that have been designed to incrementally increased the biological equivalent dose (BED) to prostate cancer, while maintaining a constant BED to normal tissue toxicity.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Maryland Proton Treatment Center, Baltimore, Maryland
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478
Recruiting
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), and HER2-negative gastric cancerovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, and prostate cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: City of Hope, Duarte, California +62 locations
Conditions: Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
Register for Updates